NLR family member X1Genealiases: CLR11.3 · DLNB26 · NOD26 · NOD5 · NOD9
Q-omics provides the consensus-scored NLRX1 profile across patient tissues and cancer cell-line models. NLRX1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, NLRX1 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, NLRX1 RNA expression shows 19,134 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCEC, LIHC, and ACC as cancer lineages where NLRX1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NLRX1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NLRX1 survival associations across molecular data types. NLRX1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NLRX1 RNA expression–survival associations across cancer types. High NLRX1 expression shows unfavorable associations in BLCA, but favorable associations in UCEC, KIRC, KIRP, THYM and ESCA. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify UCEC as the clearest survival context for NLRX1 RNA expression.
This table summarizes NLRX1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NLRX1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NLRX1 shows lower tumor expression in BRCA, KICH, READ and HNSC and higher tumor expression in LIHC and KIRP. The LIHC box plot shows higher NLRX1 RNA expression in tumor versus normal tissue (log2 FC = +0.819, t-test p < 0.001).
This table shows molecular features associated with NLRX1 in patient tissues and cancer cell lines. In patient samples, NLRX1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NLRX1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and UPPER_AERODIGESTIVE_TRACT.
